Results of the phase 3 ELOQUENT-2 trial of lenalidomide/dexamethasone with or without elotuzumab in relapsed/refractory multiple myeloma | Prof Sagar Lonial at ASCO 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, Winship Cancer Institute, Emory University, Atlanta, GA, discusses the results of the randomised, open-label ...
Author: EMJ
Added: 06/19/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 19, 2015 Category: Cancer & Oncology Source Type: podcasts
EHA 2015: Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression or death
ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma, met its primary endpoints of ...
Author: EMJ
Added: 06/13/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2015 Category: Cancer & Oncology Source Type: podcasts
Are There Clinical Trials for Myeloma Patients That Are Refractory to Lenalidomide?
In this “Ask the Expert” segment featuring Dr. Robert Orlowski from MD Anderson Cancer Center, Marilynne asks “What clinical trials are available to patients who are refractory to lenalidomide (REVLIM...
Author: patientpower
Added: 05/06/2015 (Source: Oncology Tube)
Source: Oncology Tube - May 6, 2015 Category: Cancer & Oncology Source Type: podcasts
Novel biologic agent, lenalidomide, for treating diffuse large B-cell lymphoma
Multiple novel biologic therapies are undergoing investigation for the treatment of non-Hodgkin lymphoma. At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Martin Dreyling (Ludwig-...
Author: VJHemOnc
Added: 05/05/2015 (Source: Oncology Tube)
Source: Oncology Tube - May 5, 2015 Category: Cancer & Oncology Source Type: podcasts
Phase 2/3 study of lenalidomide in relapsed/refractory DLBCL
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Andrew Davies (University of Southampton, Southampton, UK) discusses the outcomes and clinical implications of a phase 2/3 multicent...
Author: VJHemOnc
Added: 04/30/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 30, 2015 Category: Cancer & Oncology Source Type: podcasts
Phase 3 ASPIRE trial and monoclonal antibodies for treating multiple myeloma
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Keith Stewart (Mayo Clinic, Scottsdale, AZ) discusses the phase 3 ASPIRE trial comparing carfilzomib, lenalidomide, and dexamethas...
Author: VJHemOnc
Added: 04/28/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 28, 2015 Category: Cancer & Oncology Source Type: podcasts
Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma: Sustained Remission
A Multi-Center Phase II Study Report (Abstract 625).
At ASH 2014, Dr. Jia Ruan discussed her paper on Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initi...
Author: feeds
Added: 04/15/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 15, 2015 Category: Cancer & Oncology Source Type: podcasts
Phase II study of Lenalidomide in MCL
Results of the MCL-002 (SPRINT) Study (Abstract 626).
At ASH 2014, Dr. Marek Trneny discussed his abstract titled Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice ...
Author: feeds
Added: 04/15/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 15, 2015 Category: Cancer & Oncology Source Type: podcasts
Patients with MM: Elotuzumab With Lenalidomide& Dexamethasone
Phase 1b Study (Abstract 2119).
At ASH 2014, Dr. Jesus Berdeja discussed his abstract on Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with ...
Author: feeds
Added: 04/15/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 15, 2015 Category: Cancer & Oncology Source Type: podcasts
Higher-Risk MDS and CMML: Azacitidine w/ Lenalidomide or With Vorinostat vs. Azacitidine Monotherapy
Study SWOG S1117 (Abstract LBA-5).
At ASH 2014, Dr. Mikkael Sekeres discussed his abstract titled A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitid...
Author: feeds
Added: 04/15/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 15, 2015 Category: Cancer & Oncology Source Type: podcasts
Phase II Study Results: Ixazomib Maintenance Response After Ixazomib-Lenalidomide-Dexa.
At ASH 2014, Dr. Shaji Kumar discussed his abstract titled Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patient...
Author: feeds
Added: 04/15/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 15, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr Jia Ruan at ASH 2014: Phase II study of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma (Part 2 of 2)
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses the clinical relevance of a phase II study of the biologic doublet ...
Author: EMJ
Added: 04/13/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 13, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr Jia Ruan at ASH 2014: Phase II study of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma (Part 1 of 2)
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses a phase II study of the biologic doublet of lenalidomide plus ritux...
Author: EMJ
Added: 04/13/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 13, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr Andrew Davies at ASH 2014: Phase II/III study of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Andrew Davies (University of Southampton, Southampton, UK) discusses a phase II/III study comparing the efficacy and safety of lenal...
Author: EMJ
Added: 04/01/2015 (Source: Oncology Tube)
Source: Oncology Tube - April 1, 2015 Category: Cancer & Oncology Source Type: podcasts
Prof Marek Trněný at ASH 2014: Phase II SPRINT study of lenalidomide in relapsed/refractory mantle cell lymphoma
At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Marek Trněný (Charles University Hospital, Prague, Czech Republic) discusses the phase 2 SPRINT (MCL-002) study of lenalidomide ve...
Author: EMJ
Added: 03/29/2015 (Source: Oncology Tube)
Source: Oncology Tube - March 29, 2015 Category: Cancer & Oncology Source Type: podcasts
